Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exscientia plc

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Third Quarter 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Parker Moss to Join Exscientia as EVP, Corporate Development
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Details Pipeline Prioritisation Strategy
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at Upcoming Investor Conferences in September
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Second Quarter and First Half of 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for First Quarter 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
From Exscientia plc
Via Business Wire
Tickers EXAI
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Expansion of its Precision Oncology Pipeline
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business and Financial Update for the Third Quarter 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Expands Biologics Design Capability with Automated Laboratory
From Exscientia plc
Via Business Wire
Tickers EXAI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.